A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

Intranasal Delivery of mRNA Polyplexes via Rayleigh Breakup Aerosols: An In Vitro Method for Nasal Deposition and Functional Testing

744 views

⸱

DOI:

10.3791/70000

⸱

January 20th, 2026

 ,  , 

Corresponding Authors: Hao-Ying Li <hao-ying.li@kcl.ac.uk>

* These authors contributed equally

In This Article

Summary

This protocol presents Rayleigh breakup as a mild process for aerosolizing non-viral mRNA vectors. Regional deposition for aerosolized mRNA vectors is evaluated by the Alberta Idealized Nasal Inlet (AINI) model. Green fluorescence protein (GFP) expression in human lung cells represents maintenance of physicochemical and biological functions of post-aerosolized mRNA vectors.

Abstract

Intranasal delivery of mRNA therapeutics is a promising strategy for vaccination and treating respiratory diseases, offering direct immune activation at the site of pathogen entry. However, conventional aerosolization methods (e.g., ultrasonic or high-pressure nebulizers) deteriorate non-viral mRNA vectors through excessive shear forces, causing mRNAs to lose their structural integrity and biological activities. A Rayleigh breakup nasal atomizer was used to gently aerosolize polyethyleneimine (PEI)-mRNA vectors into uniform droplets. Green Fluorescent Protein (GFP)-encoding mRNA was formulated into cationic polyplexes and characterized pre- and post-aerosolization. The Rayleigh breakup process forms a continuous micro-jet of droplets with minimal shear, thereby preserving the physicochemical properties of the nanoparticles. Consistent particle size, low polydispersity index, and stable zeta potential before and after aerosolization were observed, confirming that the physicochemical properties of mRNA polyplexes were well preserved via Rayleigh breakup for aerosolization. Using an Alberta Idealized Nasal Inlet (AINI) model of the nasal airway, the PEI-mRNA aerosols were delivered. The aerosolized mRNAs were primarily deposited in the turbinate regions. Negligible fractions were found in the nasopharynx or lung-equivalent sections. In addition, the post-aerosolized mRNA polyplexes were successfully delivered to A549 human lung epithelial cells and produced detectable GFP expression. This protocol demonstrates a non-destructive intranasal mRNA delivery method using Rayleigh breakup aerosolization. It effectively maintains the physicochemical properties and biological functions of non-viral mRNA vectors, atomizing the aqueous phase into droplets of appropriate sizes for targeted nasal deposition. This protocol reveals a novel approach for effectively aerosolizing mRNAs and evaluating their regional deposition in the nasal cavity.

Introduction

Delivering vaccines to the nasal mucosa (the entry portal for many respiratory pathogens) can elicit strong local immunity and block infections at their source. The success of intranasal flu vaccines and recent approval of intranasal COVID-19 vaccines underscore the effectiveness of the nasal route for inducing both mucosal and systemic immune responses1. Intranasal delivery of mRNA vaccines is therefore attracting great interest as a strategy to prevent respiratory viral infections. A major technical challenge, however, is converting fragile mRNA polyplexes into an inhalable aerosol without compromising their stability.

Access restricted. Please log in or start a trial to view this content.

Protocol

NOTE: Culture HEK293T and A549 cell lines in complete medium consisting of Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 2% penicillin-streptomycin prior to PEI-mRNA transfection. Passage both cell lines approximately every 48 h upon reaching confluency. Seed cells at a density of 40,000 cells per cm² and culture for ~48 h. Remove the culture medium and wash cells with phosphate-buffered saline (PBS) immediately before transfection to remove residual serum and standardize transfection conditions. Autoclave all cell culture flasks, 24-well plates, PBS, pipettes, and pipette tips prior to use.

Access restricted. Please log in or start a trial to view this content.

Results

As a methods-focused manuscript, detailed results are not the primary aim; however, representative findings are presented to illustrate the expected outcomes of each part of the protocol. Figures mentioned below show example data (e.g., graphs or images) supporting the method's validity, but no new quantitative analyses beyond demonstration are included.

Droplet size and deposition pattern:
The Rayleigh breakup atomizer preserved the physicochemical properties of the mRNA .......

Access restricted. Please log in or start a trial to view this content.

Discussion

In this protocol, before aerosolizing the formulation, the mRNA is branched with PEI to enhance cellular uptake. This serves as a surrogate for LNP-mRNA delivery during in vitro validation10,15. PEI-mRNA conserves most functions of LNP formulations, including important biological and functional characteristics10. The positively charged amine groups in PEI bind negatively charged mRNA through electrostatic interactions, forming nan.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have nothing to disclose.

Acknowledgements

The authors acknowledged the financial support from the King's Undergraduate Research Fellowship (KURF) and the Student Opportunity Fund provided by King's College London.

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
50 mL centrifuge tubesSigma-Aldrich Company LimitedCLS430829-500EA
50–1000 μL pipette tipsSigma-Aldrich Company LimitedZ740031-1000EA
A549 Cell LineAmerican Type Culture CollectionATCC CRM-CCL-185
Air Flow MeterN/AN/AGeneric air flow meter may be used.
Alberta Idealized Nasal Inlet (AINI) modelTSI Incorporated (via Copley Scientific, UK)0001-01-8540
Autoclave indicator tapeSigma-Aldrich Company LimitedZ744090
DAPISigma-Aldrich Company LimitedD1306
DMEM (Dulbecco's Modified Eagle Medium)Gibco, Thermo Fisher Scientific11966025
Ethyl alcohol, pureSigma-Aldrich Company Limited32221-MPurchased via Merck
Fetal Bovine Serum (FBS)Gibco, Thermo Fisher ScientificA5256701
FormaldehydeSigma-Aldrich Company LimitedF8775
HEK293T Cell LineAmerican Type Culture CollectionATCC CRL-3216
Heraeus HERAsafe HS 12 Biosafety CabinetHeraeusN/A
Next Generation ImpactorMSP's, a Division of TSI0170-01-1000This product is also featured in the Copley Catalog, part number 5201.
Nikon DS-Qi2 Monochrome Microscope CameraNikonN/A
Nunc Cell-Culture Treated MultidishesThermo Fisher Scientific142475
Nunc EasYFlask cell culture treated flasksThermo Fisher Scientific156340
ParafilmSigma-Aldrich Company LimitedP7793-1EA
Penicillin-Streptomycin (10,000 U/mL)Gibco, Thermo Fisher Scientific15140148
Phosphate-buffered saline (PBS) TabletsThermo Fisher Scientific18912014
Polyethylenimine hydrochlorideSigma-Aldrich Company Limited764965-1GPurchased via SLS
Rayleigh Jet Nasal AtomizerResyca BV EnschedeSoft Nasal Spray Adaptor
RNAse free waterThermo Fisher ScientificJ60610.EQC
Sizing CuvetteMalvern PanalyticalZEN0040
The Folded Capillary cellMalvern PanalyticalDTS1070
Zetasizer ProMalvern PanalyticalZetasizer Pro
Zetasizer Ultra-Pro ZS Xplorer softwareMalvern PanalyticalN/A

References

  1. Akula, V. R., et al. Effect of heterologous intranasal incovacc(r) vaccination as a booster to two-dose intramuscular COVID-19 vaccination series: a randomized phase 3 clinical trial. Commun Med (Lond). 5 (1), 133(2025).
  2. Van Hoeve, W., et al.

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

Intranasal mRNA DeliveryPolyethyleneimine mRNAA549 CellsAlberta Nasal InletGFP ExpressionNon-Viral mRNA VectorsAerosolized mRNA Transfection